Frontier – A Magazine about Alligator Bioscience and Immuno-oncology
Two Alligator projects presented at ASCO.
"The American Society of Clinical Oncology (ASCO) is a professional organization for oncologists and oncology professionals from all over the world. Since the organization was founded in 1964, the number of members has grown to nearly 45,000. ASCO issues several publications, including the Journal of Clinical Oncology, and the organization’s Annual Meeting is one of the premier scientific congresses in the world, with more than 40,000 visitors. At the 2019 Annual Meeting (May 31-June 4), two of Alligator’s projects were presented: ADC-1013, which has been out-licensed to Janssen, and ATOR 1015. Having our projects presented at this world-renowned scientific event for oncology professionals says a great deal about the strong position we have in the field of immuno-oncology" comments Per Norlén, CEO Alligator Bioscience.
Read the full magazine in the pdf below.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit www.alligatorbioscience.com.
ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for global development and commercialization.